FI101303B1 - Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a][2]bentsatsepiini- ja -oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a][2]bentsatsepiini- ja -oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi

Info

Publication number
FI101303B1
FI101303B1 FI924311A FI924311A FI101303B1 FI 101303 B1 FI101303 B1 FI 101303B1 FI 924311 A FI924311 A FI 924311A FI 924311 A FI924311 A FI 924311A FI 101303 B1 FI101303 B1 FI 101303B1
Authority
FI
Finland
Prior art keywords
oxo
benzazepine
oxatzino
thiazino
pyrazino
Prior art date
Application number
FI924311A
Other languages
English (en)
Swedish (sv)
Other versions
FI101303B (fi
FI924311A (fi
FI924311A0 (fi
Inventor
Alan M Warshawsky
Gary A Flynn
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI924311A0 publication Critical patent/FI924311A0/fi
Publication of FI924311A publication Critical patent/FI924311A/fi
Application granted granted Critical
Publication of FI101303B1 publication Critical patent/FI101303B1/fi
Publication of FI101303B publication Critical patent/FI101303B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
FI924311A 1991-09-27 1992-09-25 Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi FI101303B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76728691A 1991-09-27 1991-09-27
US92948192A 1992-08-20 1992-08-20

Publications (4)

Publication Number Publication Date
FI924311A0 FI924311A0 (fi) 1992-09-25
FI924311A FI924311A (fi) 1993-03-28
FI101303B1 true FI101303B1 (fi) 1998-05-29
FI101303B FI101303B (fi) 1998-05-29

Family

ID=27117891

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924311A FI101303B (fi) 1991-09-27 1992-09-25 Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi

Country Status (16)

Country Link
US (3) US5428158A (fi)
EP (1) EP0534363B1 (fi)
JP (1) JP3173675B2 (fi)
KR (1) KR100271239B1 (fi)
AT (1) ATE155143T1 (fi)
AU (1) AU657166B2 (fi)
CA (1) CA2078758C (fi)
DE (1) DE69220744T2 (fi)
DK (1) DK0534363T3 (fi)
ES (1) ES2106112T3 (fi)
FI (1) FI101303B (fi)
GR (1) GR3024850T3 (fi)
HU (1) HU214820B (fi)
IL (1) IL103263A (fi)
NO (1) NO300848B1 (fi)
NZ (1) NZ244461A (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
ES2139669T3 (es) * 1992-08-24 2000-02-16 Merrell Pharma Inc Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa.
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
JP3563738B2 (ja) * 1993-06-11 2004-09-08 エーザイ株式会社 アミノ酸誘導体
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
WO1995001353A1 (en) * 1993-06-30 1995-01-12 Ciba-Geigy Ag Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
AU687984B2 (en) * 1994-02-14 1998-03-05 Merrell Pharmaceuticals Inc. Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
WO1995021857A1 (en) * 1994-02-14 1995-08-17 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
DK0750631T3 (da) * 1994-02-14 2000-10-23 Merrell Pharma Inc Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[c]azepin-3-ondisulfidderivater som enkephalinase- og ACE-inhibitorer
US5616775A (en) * 1994-05-05 1997-04-01 Bristol-Myers Squibb Co. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
ATE266040T1 (de) * 1994-12-21 2004-05-15 Aventis Pharma Inc Verfahren zur herstellung von zwischenprodukten von inhibitoren von enkephalinase und angiotensin konvertierendem enzym und zwischenprodukte davon
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6248729B1 (en) 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
PT1381605E (pt) * 2001-04-12 2005-03-31 Aventis Pharma Gmbh Derivados de mercaptoacetilamida um processo para a sua preparacao e utilizacao desses compostos
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) * 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101573340A (zh) 2006-11-01 2009-11-04 百时美施贵宝公司 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011525537A (ja) 2008-06-24 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性のシクロペンタチオフェン調節剤およびその使用
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
EP3552017B1 (en) 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
ES8801833A1 (es) * 1985-04-30 1988-02-16 Lilly Co Eli Un procedimiento para la preparacion de un compuesto.
ZA874107B (fi) * 1986-06-13 1987-12-09
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
NZ241023A (en) * 1990-12-21 1994-10-26 Merrell Dow Pharma Condensed benzazepine derivatives and pharmaceutical compositions
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
WO1993005809A1 (en) * 1991-09-16 1993-04-01 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase

Also Published As

Publication number Publication date
IL103263A0 (en) 1993-02-21
HUT65192A (en) 1994-05-02
US5428158A (en) 1995-06-27
NO923744D0 (no) 1992-09-25
NO300848B1 (no) 1997-08-04
ES2106112T3 (es) 1997-11-01
FI101303B (fi) 1998-05-29
JPH05294963A (ja) 1993-11-09
NZ244461A (en) 1994-09-27
IL103263A (en) 1996-11-14
JP3173675B2 (ja) 2001-06-04
NO923744L (no) 1993-03-29
EP0534363A2 (en) 1993-03-31
EP0534363A3 (en) 1993-06-09
ATE155143T1 (de) 1997-07-15
CA2078758A1 (en) 1993-03-28
DK0534363T3 (da) 1997-09-22
CA2078758C (en) 2003-12-09
GR3024850T3 (en) 1998-01-30
FI924311A (fi) 1993-03-28
HU9203074D0 (en) 1992-12-28
AU657166B2 (en) 1995-03-02
DE69220744T2 (de) 1997-11-13
AU2524592A (en) 1993-04-01
FI924311A0 (fi) 1992-09-25
HU214820B (hu) 1998-06-29
EP0534363B1 (en) 1997-07-09
KR100271239B1 (ko) 2001-02-01
US5486513A (en) 1996-01-23
DE69220744D1 (de) 1997-08-14
US5529996A (en) 1996-06-25
KR930006027A (ko) 1993-04-20

Similar Documents

Publication Publication Date Title
FI101303B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a][2]bentsatsepiini- ja -oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi
FI101302B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-karboksialkyyli-2-okso)metyyliamino-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino[2,1-a]bentsatsepiini- ja -[1,4]oksatsino- ja -tiatsino[3,4-a][2]bentsatsepiini-4-karboksyylihappojohdannaisten valmistamiseksi
FI943363A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi
FI892881A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten aminohappojohdannaisten va lmistamiseksi
IL105727A (en) 7-(2-mercapto-acetamido)-octahydro-6-oxopyrido[2,1-a][2]-benzazepine derivatives analogs thereof their preparation and pharmaceutical enkephalinase-inhibiting compositions containing them
NO177312C (no) Fremgangsmåte for fremstilling av hirudinderivater med forsinket virkning
FI880467A (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 3,4-dihydro-2H-bentsopyraanien valmistamiseksi
FI104075B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-karboksitienyylikarbamoyylipyrrolidin-4-yylitiokarbapeneemi-3-karboksyylihappojohdannaisten valmistamiseksi
AU1634388A (en) Cyclic anticoagulant peptides
AU1634288A (en) Cyclic anticoagulant peptides
FI903571A0 (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
CA2141563A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Tricyclic Derivatives Useful as Inhibitors of Enkephalinase
IT9019323A0 (it) Procedimento di preparazione di l-a-glicerilfosforil-d-myoinositolo e suoi sali da fosfatidi grezzi o parzialmente purificati
FI893121A0 (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
HUT65256A (en) Process for producing 2-mercapto methylene-tetrahydronaphtalene-2-carboxamide derivatives and pharmaceutical preparations containing them
ITMI911934A0 (it) Procedimento per la produzione di vanadio bis-areni da ossicloruro di vanadio
NO880034D0 (no) Fremgangsmaate for fremstilling av krystallinsk aminobeskyttet beta-benzyl-l-aspartinsyre.

Legal Events

Date Code Title Description
MA Patent expired